kt-579
·Code: KT-579
kt-579: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Kymera Therapeutics, Inc. (KYMR) | Phase 1 |
Clinical Trials (1)
A Phase 1, Randomized, Placebo-Controlled, First-in-Human, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered KT-579 in Healthy Adult Participants
Frequently asked questions
Who is developing kt-579?
kt-579 is being developed by Kymera Therapeutics, Inc..
How many clinical trials involve kt-579?
BioSniper tracks 1 clinical trial involving kt-579.
Get deeper analysis on kt-579
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis